Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy.
Journal: Frontiers in neurology
Published: August 09, 2024
fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study.
Journal: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
Published: March 08, 2024
Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
Journal: Journal of clinical immunology
Published: March 08, 2024
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases.
Journal: Journal of clinical immunology
Published: January 09, 2024
Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Journal: International immunopharmacology
Published: October 17, 2023
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.
Journal: Immunotherapy advances
Published: October 03, 2023
Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy.
Journal: Annals of clinical and translational neurology
Published: September 14, 2023
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants.
Journal: Journal of clinical immunology
Published: July 28, 2023
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
Journal: Journal of clinical immunology
Published: July 10, 2023
Evaluation of body weight-based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency.
Journal: Pulmonary pharmacology & therapeutics
Published: June 30, 2023
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
Journal: Journal of the peripheral nervous system : JPNS
Published: April 14, 2023
Last Updated: 09/26/2026